Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer opening to investor input

Executive Summary

Pfizer is taking further steps to increase transparency and allay investors' concerns about executive compensation; the company's board will meet with the largest institutional shareholders this fall to discuss its governance and compensation policies. Investors had grown frustrated with former CEO Hank McKinnell, and Pfizer's performance, which was exacerbated by McKinnell's severance package of nearly $200 million (1"The Pink Sheet" Jan. 1, 2007, In Brief). Despite taking the firm in a new direction with a major restructuring, patience with CEO Jeffrey Kindler may already be waning (2"The Pink Sheet" April 30, 2007, p. 6)...

You may also be interested in...



Kindler’s Honeymoon Over? Analysts Press Pfizer Execs On Series Of Stumbles

The sheen of Pfizer's new management team - including CEO Jeffrey Kindler - may be beginning to wear off, based on analyst comments during Pfizer's April 20 first-quarter earnings call

McKinnell not leaving empty-handed

McKinnell could receive nearly $200 million in severance payments and benefits from the company, according to a Dec. 21 Securities & Exchange Commission filing. The package includes a lump-sum pension payment of $82 milllion, $78 million in deferred compensation, $11.9 million in severance as well as bonus and unused vacation payments and stock options potentially worth nearly $25 million...

US High Court Punts On ‘Objective Falsity’ FCA Standard

Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel